Perrigo Company Public Limited Company (NYSE:PRGO) agreed to acquire Generic Retin-A® Portfolio from Matawan Pharmaceuticals, LLC on December 17, 2015. Generic Retin-A® Portfolio reported sales of approximately $287 million for the 12-months ending October 2015. The transaction is expected to close in the first quarter of 2016. The transaction is expected to immediately exceed Perrigo's ROIC threshold and add more than $0.20 in adjusted EPS within the first 12 months post-close after the exclusion of estimates for intangible amortization, transaction costs and integration related expenses. Jefferies LLC acted as financial advisor for Matawan Pharmaceuticals. Sheryl Orr, Robert Robison, Harry Robins, Scott Stempel, Kenneth Kail, Sarah Wong, Martin D'Halluin, Brian Clement and Stephanie Lax of Morgan Lewis acted as legal advisor to Perrigo.

Perrigo Company Public Limited Company (NYSE:PRGO) completed the acquisition of Generic Retin-A® Portfolio from Matawan Pharmaceuticals, LLC for approximately $420 million on January 22, 2016. Under the terms of agreement, Perrigo paid consideration in cash. The transaction was funded through funded primarily by borrowings under 2014 Revolver and 2015 Revolver.